Is It MS? Application of the Diagnostic Criteria and Identification of Red Flags

Volume 4, Issue 7

Is It MS? Application of the Diagnostic Criteria and Identification of Red Flags

In this issue:

Accurately diagnosing multiple sclerosis and differentiating MS from alternate disorders can be challenging in clinical settings. What is a typical clinical and radiological presentation for MS? Does a demyelinating event exhibit both polyphasic and multifocal qualities compatible with MS? How well can the McDonald criteria aid in differentiating MS from other neurological conditions? What are the red flags suggestive of an alternate diagnosis that clinicians need to recognize?

These are some of the questions neuroimmunologist Dr. Gabrielle Macaron from Saint Joseph University in Beirut, Lebanon and the Cleveland Clinic in Ohio explores in this issue of eMultipleSclerosis Review.

Learning objectives:

Identify clinical and radiological red flags that warrant evaluation of an alternate diagnosis to MS.
Describe common errors in the interpretation and application of the MS diagnostic criteria.

Author:

Gabrielle Macaron, MD

Neuroimmunologist, Saint Joseph University
Hotel Dieu de France Hospital
Beirut, Lebanon

Adjunct staff, Mellen Center for Multiple Sclerosis
Cleveland Clinic
Cleveland, OH

Guest Faculty Disclosures

Dr. Macaron has indicated that she has received honoraria from Roche Laboratories, Inc., Novartis and Biogen Idec. She has also received consulting fees Roche Laboratories, Inc. and Novartis.

Unlabeled/Unapproved Uses

Dr. Macaron has indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.   

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures:

Dr. Macaron has indicated that she has received honoraria from Roche Laboratories, Inc., Novartis and Biogen Idec. She has also received consulting fees Roche Laboratories, Inc. and Novartis.

Unlabeled/Unapproved Uses:

Dr. Macaron has indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.   

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: June 7, 2022
Expiration date: June 6, 2024

Start Issue